Should Quality-Oriented Investors Explore ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN)?

In this article we will dive into ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) as a possible candidate for quality investing. Investors should always do their own research, but we noticed ASTRAZENECA PLC-SPONS ADR showing up in our Caviar Cruise quality screen, which makes it worth to investigate a bit more.

A Deep Dive into ASTRAZENECA PLC-SPONS ADR's Quality Metrics.

• ASTRAZENECA PLC-SPONS ADR has demonstrated significant revenue growth over the past 5 years, with a 15.71% increase. This underscores the company's ability to adapt to market dynamics and capitalize on growth opportunities.
• With a notable ROIC excluding cash and goodwill at 101.0%, ASTRAZENECA PLC-SPONS ADR demonstrates its commitment to generating sustainable returns for shareholders. This metric emphasizes the company's effective use of capital and its ability to deliver long-term value.
• With a favorable Debt/Free Cash Flow Ratio of 4.36, ASTRAZENECA PLC-SPONS ADR showcases its sound financial discipline and cash flow management. This ratio indicates the company's ability to service its debt obligations while maintaining sufficient free cash flow for future investments or operational needs.
• ASTRAZENECA PLC-SPONS ADR exhibits impressive Profit Quality (5-year) with a 759.0% ratio, reflecting its consistent ability to generate high-quality profits. This metric underscores the company's strong financial performance and commitment to delivering sustainable earnings.
• ASTRAZENECA PLC-SPONS ADR has consistently achieved strong EBIT growth over the past 5 years, with a 29.65% increase. This underscores the company's effective management of its operating income and suggests a positive outlook for future profitability.
• ASTRAZENECA PLC-SPONS ADR demonstrates a remarkable trend where its EBIT 5-year growth exceeds its Revenue 5-year growth. This indicates the company's ability to enhance its profitability through improved cost control and operational efficiency.

What is the full fundamental picture of NASDAQ:AZN telling us.

Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.

Overall AZN gets a fundamental rating of 6 out of 10. We evaluated AZN against 198 industry peers in the Pharmaceuticals industry. AZN scores excellent on profitability, but there are some minor concerns on its financial health. AZN may be a bit undervalued, certainly considering the very reasonable score on growth

Check the latest full fundamental report of AZN for a complete fundamental analysis.

More ideas for quality investing can be found on ChartMill in our Caviar Cruise screen.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.